| Literature DB >> 28713576 |
Sharon Tirosh-Levy1, Boris Gelman2, Doni Zivotofsky3, Lara Quraan1, Evgeny Khinich2, Abdelmajeed Nasereddin4, Ziad Abdeen4, Amir Steinman1.
Abstract
Equine encephalosis virus (EEV) is an orbivirus transmitted by Culicoides species. Most infected horses show mild clinical signs and mortality is usually very low. EEV is closely related and similarly transmitted to other, more pathogenic and economically important, orbiviruses such as African horse sickness virus (AHSV), bluetongue virus (BTV) and epizootic haemorrhagic disease viruses (EHDV), and may serve as an indicator for possible transmission of the latter. Israel has been reported to be endemic for EEV since 2001. This study was initiated to re-evaluate the current seroprevalence and risk factors for EEV exposure in Israel, and to assess, for the first time, the seroprevalence of EEV in Palestine and Jordan. Three hundred and sixteen serum samples were collected from apparently healthy horses at 21 farms in Israel, 66 horses at nine farms in Palestine and 100 horses at three farms in Jordan. The presence of EEV antibodies was detected by a serum neutralization assay. Seroprevalence of EEV was 58.2% (184/316 horses) in Israel, 48.5% (32/66 horses) in Palestine and 2% (2/100 horses) in Jordan. Seroprevalence in Jordan was significantly lower than in Israel and Palestine (P < 0.001). The farm (P < 0.001) and horse age (P = 0.003) were found as significant risk factors for EEV exposure in Israel in multivariable statistical analysis. The results of this study further demonstrate that EEV is no longer limited to South Africa and is endemic in both Israel and Palestine and horses in Jordan were also exposed to this virus emphasizing the potential of pathogens to invade new ecological niches.Entities:
Keywords: Equine encephalosis virus; arbovirus; horse; seroprevalence
Year: 2017 PMID: 28713576 PMCID: PMC5488184 DOI: 10.1002/vms3.58
Source DB: PubMed Journal: Vet Med Sci ISSN: 2053-1095
Figure 1Geographical distribution of the farms sampled at the study and EEV seroprevalence at each farm. Colour gradient correlates with EEV seroprevalence in each location, with darker colours represent higher seroprevalence.
Figure 2The distribution of EEV‐specific antibody titres, as detected by serum neutralization assay, in asymptomatic horses in Israel (light grey), the Palestine (dark grey) and Jordan (black).
Univariale analysis of risk factors considered for an association with Equine enchephalosis virus seropositivity in horses sampled in Israel and Palestine
| Variable | Category (n) | Number of carriers (%) | OR (95% CI) |
|
|
|---|---|---|---|---|---|
| Israel | 184/316 (58.2%) | 1.48 (0.87–2.51) | 0.172 | 0.172 | |
| Palestine | 32/66 (48.5%) | Ref | |||
|
| Northern Israel | 78/142 (54.9%) | 3.66 (1.62–8.25) |
|
|
| Central Israel | 85/105 (81%) | 12.75 (5.25–30.98) |
| ||
| Southern Israel | 12/33 (36.4%) | 1.71 (0.62–4.76) | 0.433 | ||
| Golan Heights | 9/36 (25%) | Ref | |||
|
| Mare | 92/181 (50.8%) | 0.57 (0.37–0.87) |
|
|
| Stallion | 11/26 (42.3%) | 0.4 (0.18–0.92) |
| ||
| Gelding | 113/175 (64.6%) | Ref | |||
|
| Under three years | 3/27 (11.1%) | Ref |
| |
| Three to six years | 34/70 (48.6%) | 7.56 (2.13–26.81) |
| ||
| Six to nine years | 50/84 (59.5%) | 11.76 (3.35–4126) |
| ||
| Nine to twelve years | 50/83 (60.2%) | 12.12 (3.45–42.57) |
| ||
| Over twelve years | 74/111 (66.7%) | 16 (4.62–55.38) |
|
| |
|
| Mixed | 114/213 (53.5%) | Ref |
| |
| Thouroghbred | 6/8 (75%) | 2.61 (0.57–11.92) | 0.295 | ||
| Missurie Foxtrot | 3/3 (100%) | 6.08 (0.46–80.29) | 0.252 | ||
| Paint Horse | 5/14 (35.7%) | 0.48 (0.16–1.43) | 0.27 | ||
| Quarter Horse | 48/80 (60%) | 1.3 (0.77–2.19) | 0.357 | ||
| Shire | 1/1 (100%) | – | 1 | ||
| Warmblood | 6/8 (75%) | 2.61 (0.57–11.92) | 0.295 | ||
| Pony | 10/13 (76.9%) | 2.89 (0.81–10.29) | 0.15 | ||
| Tinker | 0/2 (0%) | – | 0.22 | ||
| Tennessee Walking Horse | 9/10 (90%) | 7.82 (1.08–56.51) |
| ||
| Appaloosa | 3/7 (42.9%) | 0.65 (0.16–.67) | 0.708 | ||
| Arabian | 7/18 (38.9%) | 0.55 (0.21–1.44) | 0.32 | ||
|
| Stall | 83/118 (70.3%) | 2.41 (1.41–4.11) |
|
|
| Paddock | 43/81 (53.1%) | 1.15 (0.65–2.02) | 0.666 | ||
| Pasture | 58/117 (49.6%) | Ref | |||
|
| Dark | 99/167 (59.3%) | 0.98 (0.54–1.81) | 1 | 0.781 |
| Light | 50/91 (54.9%) | 0.82 (0.42–1.61) | 0.612 | ||
| Coloured | 34/57 (59.6%) | Ref |
Statistically significant values are written in bold
Figure 3The association of EEV seroprevalence with age. No significant differences were observed between the different groups, except for the youngest age group (under 3 years) in which the seroprevalence was significantly lower (P = 0.005). A linear correlation was found between age and seroprevalence (P < 0.001).